FHIR IG analytics
| Package | us.nlm.vsac |
| Resource Type | ValueSet |
| Id | ValueSet-2.16.840.1.113883.3.1444.3.189.json |
| FHIR Version | R4 |
| Source | https://vsac.nlm.nih.gov/valueset/2.16.840.1.113883.3.1444.3.189/expansion |
| URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.189 |
| Version | 20241206 |
| Status | active |
| Date | 2024-12-06T01:13:08-05:00 |
| Name | PembrolizumabInjectable |
| Title | Pembrolizumab Injectable |
| Realm | us |
| Authority | hl7 |
| Purpose | (Clinical Focus: The purpose of this value set is to represent concepts of medication Pembrolizumab.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication Pembrolizumab; generic; prescribable; injectable.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.) |
Resources that use this resource
Resources that this resource uses
Narrative
No narrative content found in resource
Source1
{
"resourceType": "ValueSet",
"id": "2.16.840.1.113883.3.1444.3.189",
"meta": {
"versionId": "11",
"lastUpdated": "2024-12-06T01:13:08.000-05:00",
"profile": [
"http://hl7.org/fhir/StructureDefinition/shareablevalueset",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
]
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-author",
"valueContactDetail": {
"name": "American Society of Clinical Oncology Author"
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
"valueDate": "2025-04-08"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
"valueDate": "2024-12-06"
}
],
"url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.189",
"identifier": [
{
"system": "urn:ietf:rfc:3986",
"value": "urn:oid:2.16.840.1.113883.3.1444.3.189"
}
],
"version": "20241206",
"name": "PembrolizumabInjectable",
"title": "Pembrolizumab Injectable",
"status": "active",
"date": "2024-12-06T01:13:08-05:00",
"publisher": "American Society of Clinical Oncology Steward",
"jurisdiction": [
{
"coding": [
{
"system": "urn:iso:std:iso:3166",
"code": "US"
}
]
}
],
"purpose": "(Clinical Focus: The purpose of this value set is to represent concepts of medication Pembrolizumab.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication Pembrolizumab; generic; prescribable; injectable.),(Exclusion Criteria: Excludes concepts that represent non-prescribable branded drugs, components or ingredients.)",
"compose": {
"include": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"concept": [
{
"code": "1657746",
"display": "pembrolizumab 50 MG Injection"
},
{
"code": "1657750",
"display": "4 ML pembrolizumab 25 MG/ML Injection"
}
]
}
]
},
"expansion": {
"identifier": "urn:uuid:475c1ba4-0696-4403-beb7-6b86e822ab4a",
"timestamp": "2025-05-23T21:54:19-04:00",
"total": 2,
"contains": [
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657746",
"display": "pembrolizumab 50 MG Injection"
},
{
"system": "http://www.nlm.nih.gov/research/umls/rxnorm",
"version": "05052025",
"code": "1657750",
"display": "4 ML pembrolizumab 25 MG/ML Injection"
}
]
}
}